Poor prognosis and drug resistance seen in pancreatic ductal adenocarcinoma (PDAC) is related to the activity of a tumor stem cell population that helps the tumor to regenerate after surgery or chemotherapy. The biology of these tumor stem cells remains poorly characterized, hampering the development of better treatment options.

In this presentation, Dr. Carles Barceló discusses the mechanisms of oncogenic addiction and resistance to adjuvant treatment seen in PDAC using patient-derived organoids. In addition, he also discusses his work on SARS-CoV-2 infection modeling using human airway organoid models.

This presentation was part of the live webinar on “Organoid Models for Studying Pancreatic Diseases”, hosted by STEMCELL Technologies on Tuesday, May 30, 2023.